Rodman and Renshaw Presentation 11-7-06
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
__________________
Date
of
Report (Date of earliest event reported):
November
7, 2006
BIOSANTE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-31812
|
58-2301143
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification Number)
|
|
111
Barclay Boulevard
Lincolnshire,
Illinois
|
60069
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(847)
478-0500
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
| £ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
| £ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| £ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
| £ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
Item
7.01. Regulation
FD Disclosure.
Representatives
of BioSante Pharmaceuticals, Inc. (“BioSante”) intend to make presentations at
investor conferences and in other forums using slides containing the information
attached to this Current Report on Form 8-K as Exhibit 99.1. BioSante is
furnishing the text of these slides pursuant to the Securities and Exchange
Commission’s Regulation FD. This information is furnished pursuant to
Item 7.01 of Form 8-K and shall not be deemed to be “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”), or otherwise subject to the liabilities of that section, nor
shall it be deemed to be incorporated by reference in any filing under the
Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act,
except as expressly set forth by specific reference in such filing. BioSante
expects to use these slides, in whole or in part, and possibly with
modifications, in connection with presentations to investors, analysts and
others during the remainder of 2006.
By
filing
this Current Report on Form 8-K and furnishing this information, BioSante makes
no admission as to the materiality of any information in this report that is
required to be disclosed solely by reason of Regulation FD.
The
information contained in the slides is summary information that is intended
to
be considered in the context of BioSante’s Securities and Exchange Commission
(“SEC”) filings and other public announcements that BioSante may make, by press
release or otherwise, from time to time. BioSante undertakes no duty or
obligation to publicly update or revise the information contained in this
report, although it may do so from time to time as its management believes
is
warranted. Any such updating may be made through the filing of other reports
or
documents with the SEC, through press releases or through other public
disclosure.
When
included in this Current Report on Form 8-K, the words “expects,” “intends,”
“anticipates,” “believes,” “estimates,” and analogous expressions are intended
to identify forward-looking statements as defined within the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements are subject
to
risks and uncertainties that could cause actual results to differ materially
from those projected or implied. Such potential risks and uncertainties relate,
but are not limited, to, in no particular order: the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals and achieving
market acceptance. More detailed information on these and additional factors
which could affect BioSante’s operating and financial results are described in
BioSante’s filings with the Securities and Exchange Commission, including its
most recent annual report on Form 10-K. BioSante urges all interested parties
to
read these reports to gain a better understanding of the many business and
other
risks that the company faces. Additionally, BioSante undertakes no obligation
to
publicly release the results of any revisions to these forward-looking
statements, which may be made to reflect events or circumstances occurring
after
the date hereof or to reflect the occurrence of unanticipated events.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits.
|
Exhibit
No.
|
Description
|
|
99.1
|
BioSante
Pharmaceuticals, Inc. Investor Presentation (furnished
herewith)
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
BIOSANTE
PHARMACEUTICALS, INC.
By: /s/
Stephen M. Simes
Stephen
M. Simes
President
and Chief Executive Officer
Dated:
November 7, 2006
BIOSANTE
PHARMACEUTICALS, INC.
CURRENT
REPORT ON FORM 8-K
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
Method
of Filing
|
|
99.1
|
BioSante
Pharmaceuticals, Inc. Investor Presentation
|
Furnished
herewith
|